Rezolute Reports Positive Interim Data In Phase 3 UpLIFT Study For Ersodetug For Tumor HI
Rezolute Inc. reported positive interim Phase 3 upLIFT results for ersodetug in tumor-related hyperinsulinism. The trial enrolled 8 of 16 planned patients; 6 of the first 8 met the primary endpoint, with ≥50% reductions in IV glucose needs during the 8-week pivotal phase, and all six stopped IV glucose while on treatment. No drug-related adverse events were reported. Rezolute expects topline results in H2 2026.
How this was made
The 30-second read
Why it matters
The interim readout increases perceived clinical efficacy and safety confidence for ersodetug, potentially improving financing/valuation expectations for Rezolute while awaiting full topline after complete enrollment.
Market read
Material clinical datapoint for RZLT with a defined next milestone (2H26 topline) and immediate repricing potential based on interim responder/safety metrics.
What to watch
One patient withdrew consent due to advanced cancer progression and was counted as a non-responder; also, the open-label extension is not controlled, so durability and comparative benefit remain unproven.
Background
Ersodetug (fully human monoclonal antibody) is being developed for refractory hypoglycemia from tumor-related hyperinsulinism and other hyperinsulinism forms; upLIFT is a Phase 3 pivotal study.
Ticker impact
Rezolute reported positive interim Phase 3 upLIFT results for ersodetug, with 6/8 meeting the primary endpoint and no drug-related AEs.
Near-term upside bias possible as traders reprice Phase 3 success odds; magnitude depends on broader biotech risk appetite and follow-on data.
The article provides concrete interim responder data (6/8) and safety (no drug-related AEs) plus a clear next catalyst window (2H26 topline).
Market effects
Supports sentiment for ultra-rare disease oncology/metabolic hypoglycemia therapeutics and monoclonal antibody approaches targeting insulin receptor signaling.
Primarily US microcap/small-cap biotech sentiment; limited direct regional spillover beyond biotech risk-on/off.
Clinical efficacy signal may attract broader global biotech interest, but impact is likely confined until full enrollment topline.
Counterpoint
Interim data are from only 8 enrolled patients; responder rate could regress with the remaining cohort, and the primary endpoint is based on a specific IV glucose reduction window.
Key entities
- companyRezolute Inc.
Company running the Phase 3 upLIFT study of ersodetug and reporting positive interim results.
- drugErsodetug
Allosteric monoclonal antibody targeting insulin receptor over-activation to correct hypoglycemia.
- clinical_trialupLIFT study
Phase 3 trial enrolling 16 participants; interim data reported from 8 patients.
